Combination of wound rinse solution and cold plasma for the treatment of wounds

Abstract

The present invention relates to the use of a combination of a wound rinse solution and cold atmospheric plasma to treat a wound.The present invention further relates to a method for treating a wound comprising rinsing the wound with the wound solution and treating the wound with cold atmospheric plasma.

Description

[Technical field]

[0001] The present invention relates to the use of a combination of a wound rinse solution and cold air plasma for treating a wound.The present invention further relates to a method for treating a wound comprising the steps of rinsing the wound with a wound solution and treating the wound with cold air plasma. [Background technology]

[0002] Many wounds, especially chronic wounds, heal very slowly or do not heal at all. This is frequently due to severe infections, often caused by bacteria, that can no longer be controlled or can only be barely controlled with antibiotics due to resistance.

[0003] Large, externally accessible, and often chronic wounds are treated with wound rinse solutions to cleanse the wound while removing tissue residues, necrotic particles, excess exudate, deposits, dressing residues, cellular debris, etc., and biofilms are also removed, often with antiseptics and surgical debridement.

[0004] Such wound rinse solutions are generally isotonic (physiological) and can contain various disinfectants, which include bactericidal, bacteriostatic, fungicidal, fungistatic and / or virucidal active substances, depending on the site where they are used and the cause of the infection. Some wound rinse solutions also contain active oxygen, such as singlet oxygen, which can be first complexed (e.g., sodium hypochlorite) and then released (Kammerlander et al., pro care 08 / 2012, pp. 26-29). However, not all wounds can be healed with wound rinse solutions, and they often recur after treatment. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Kammerlander et al., pro care 08 / 2012, pp. 26-29 Summary of the Invention

[0006] The present invention addresses this technical problem as described herein and as defined in the claims. [The present invention 1001] 1. Use of a combination of a wound rinse solution and cold air plasma to treat a wound, wherein a vacuum activated charcoal dressing is used. [The present invention 1002] Use of the present invention 1001 by applying the activated charcoal-containing portion of the activated charcoal dressing directly to the wound. [The present invention 1003] The process is as follows: (a) rinsing the wound with a wound rinse solution; and (b) treating the wound with cold atmospheric plasma 23. A method for treating a wound comprising: [The present invention 1004] (c) Repeatedly rinsing the wound with a wound rinse solution. The method of the present invention 1003 further comprising: [The present invention 1005] (d) applying a evacuated activated charcoal dressing to the wound. The method of any one of claims 1003 and 1004, further comprising: [The present invention 1006] Any of the methods of claims 1003 to 1005, further comprising the step of treating any wound rinse solution remaining on the wound with cold air plasma. [The present invention 1007] The use of any of invention 1001 or invention 1002 or any of the methods of inventions 1003 to 1006, wherein the wound rinse solution contains active oxygen. [The present invention 1008] The use of any of claims 1001, 1002 or 1007 or the method of any of claims 1003 to 1007, wherein the wound rinse solution contains singlet oxygen. [The present invention 1009] The use of any of 1001, 1002, 1007 or 1008, or any of the methods of 1003-1008, wherein ambient air or argon is used for plasma generation. [The present invention 1010] The use of any of 1001, 1002, or 1007-1009 or the method of any of 1003-1009, wherein the salt content of the wound rinse solution is less than 4% by weight. [Brief description of the drawings]

[0007] [Figure 1]Figure 1A: shows a patient as described in Example 4 before treatment of a wound according to the invention. The patient had an infected driveline. Figure 1B: shows a PET / CT image of a patient as described in Example 4 before treatment of a wound according to the invention. The patient had an infected driveline. Figure 1C: shows a patient as described in Example 4 3 weeks after treatment of a wound according to the invention. [Diagram 2] Shown is a driveline with an activated charcoal NPWT dressing: the activated charcoal film (1) is placed in the wound bed, encasing the driveline and protruding from the wound and covering the surrounding skin area; a grey-black NPWT sponge (2) is placed on the activated charcoal film. [Diagram 3] 1 shows repeated rinsing and sealing of the wound with cold plasma (CAP) and activated charcoal NPWT. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0008] explanation Surprisingly in the context of the present invention, the combination of wound rinse solution and cold air plasma (hereinafter also referred to as "cold plasma" or "CAP") is very suitable for use in treating wounds. As can be shown, chronic wounds can be treated to a large extent, and the number or intensity of recurrences can be significantly reduced. No undesirable side effects were observed. Treating wounds with wound rinse solution alone, such as ActiMaris®, did not lead to satisfactory success, but the combination of wound rinse solution and cold plasma was found to lead to satisfactory, and in this case surprisingly, therapeutic success in treating wounds.

[0009] The present invention therefore relates to the use of a combination of a wound rinse solution and cold air plasma to treat wounds.

[0010] Alternatively, the present invention relates to the use of a combination of a wound rinse solution and cold air plasma for use in treating wounds.

[0011] In one embodiment of the present invention, activated charcoal dressings, preferably evacuated activated charcoal dressings, are also used for the treatment of wounds. Examples of suitable activated charcoal dressings are known to those skilled in the art and include Actisorb®, Askina® Carbosorb, CarboFlex®, Vliwaktiv® AG absorbent compresses, among others. Dressings composed of activated charcoal and vacuum sponges can be used as evacuated activated charcoal dressings, e.g., advanced negative pressure wound therapy (aNPWT) or activated charcoal NPWT, as known to those skilled in the art. When using activated charcoal NPWT (aNPWT), intensive wound therapy with more frequent changes (every 2-3 days) is possible, because the carbon film ensures active cleaning. The release of oxygen radicals is clearly desirable in this use.

[0012] The aNPWT treatment method is however distinct from the NPWT standard methods from the prior art, such as Avance® Flex (Molnlycke®). It involves the use of a green sponge, which allows detection of blood loss by the discoloration of the sponge. This method from Molnlycke Health Care clearly precludes the use of hypochlorite solutions and hydrogen peroxide due to the release of oxygen radicals. It is simply a modified NPWT procedure (use of a green sponge), but does not involve activated charcoal dressings in the sense of wound cleansing as used in aNPWT.

[0013] When using activated carbon NPWT, the activated carbon can also immobilize residual microorganisms under the vacuum sponge, thus reducing the repeated progression of infection. According to the present invention, the progress of treatment can therefore be further supported by a combination of wound rinse solution and cold air plasma. In the application according to the present invention, activated carbon dressings are particularly preferred, where the activated carbon-containing portion is applied (i.e. placed) directly onto the wound. This allows bacteria to be bound without a barrier. A preferred activated carbon dressing that allows for direct application of the activated carbon-containing portion of the dressing is Zorflex® Activated Carbon (Chemviron, UK). Until now, no company has recommended a carbon film in direct contact with the wound bed.

[0014] The present invention further comprises: (a) rinsing the wound with a wound solution; and (b) treating the wound with cold atmospheric plasma The present invention relates to a method for treating a wound, comprising:

[0015] A wet film of rinse solution preferably remains in the wound bed before the wound is treated with the cold air plasma.

[0016] In one embodiment of the invention, the method also comprises the further step of: (c) repeatedly rinsing the wound with a wound rinse solution (preferably with the same wound rinse solution as in step (a)); and / or (d) applying the activated charcoal dressing to the wound. may include.

[0017] According to the present invention, steps (a), (b) and optionally (c) and / or (d) are preferably carried out in the order (a), (b), ((c), (d)).

[0018] The method according to the invention may further comprise the further step of treating the wound rinse solution with cold air plasma, preferably before step (a) and / or before step (c).

[0019] As regards step (d), it is preferably a vacuum activated carbon dressing according to the invention. Examples of suitable (vacuum) activated carbon dressings are known to the person skilled in the art, as already explained above.

[0020] The present invention also relates to (a) rinsing the wound with a wound solution; and (b) treating the wound with cold atmospheric plasma The present invention relates to a combination of a wound rinse solution and cold air plasma for use in a method for treating a wound, comprising:

[0021] A wet film of rinse solution preferably remains in the wound bed before the wound is treated with the cold air plasma.

[0022] In one embodiment of the invention, the combination of wound rinse solution and cold air plasma described above for use in a method for treating a wound may also comprise the further steps of: (c) repeatedly rinsing the wound with a wound rinse solution (preferably with the same wound rinse solution as in step (a)); and / or (d) applying the activated charcoal dressing to the wound. may include.

[0023] According to the present invention, steps (a), (b) and optionally (c) and / or (d) are preferably carried out in the order: (a), (b), ((c), (d)).

[0024] In one embodiment of the invention, the combination of wound rinse solution and cold air plasma described above for use in a method for treating a wound may also comprise the further step of treating the wound rinse solution with cold air plasma, preferably prior to step (a) and / or prior to step (c).

[0025] As regards step (d), it is preferably a vacuum activated carbon dressing according to the invention. Examples of suitable (vacuum) activated carbon dressings are known to the person skilled in the art, as already explained above.

[0026] In this regard, the present invention alternatively relates to a combination of a wound rinse solution and cold air plasma for use in treating a wound, where the wound rinse solution is designed for rinsing the wound and the cold air plasma is designed for treating the wound.

[0027] A wet film of rinse solution preferably remains in the wound bed before the wound is treated with the cold air plasma.

[0028] Additionally, in one aspect, the present invention also relates to a combination of a wound rinse solution, cold air plasma and an activated charcoal dressing for use in treating a wound, wherein the wound rinse solution is designed for rinsing the wound, the cold air plasma injection is designed for treating the wound, and the activated charcoal dressing is prepared for application to the wound.

[0029] Wound rinsing solutions related to the present invention include in particular solutions suitable for wound cleansing and adapted to be used to rinse or cleanse wounds, as known to those skilled in the art. In one embodiment, these are wound rinsing solutions that are sterile, painless or nearly painless, physiological, non-irritating or caustic, and / or can be heated to at least 28°C. Wound rinsing solutions related to the present invention include wound rinsing solutions that contain salts (e.g., NaCl, sea salt) and / or electrolytes (e.g., sodium, potassium, calcium), alcohols (e.g., ethanol, isopropanol, phenoxyethanol), quaternary ammonium compounds (e.g., benzalkonium, cetylpyridinium, octenidine, polyhexanide), iodine-containing compounds (e.g., povidone-iodine / PVP iodine), chlorine-containing compounds (e.g., chlorhexidine), hexetidine, vibrocatol, hexafluorophosphate ... The compositions may include, for example, ethanol, taurolidine, enzymes (e.g., varidase, fibrolan, and / or (further) bactericidal, bacteriostatic, fungicidal, fungistatic, and / or virucidal components (disinfectants). Such bactericidal, bacteriostatic, fungicidal, fungistatic, and / or virucidal components may include, for example, antibiotics, reactive compounds such as ROS (reactive oxygen species) and / or RNS (reactive nitrogen species). An example of ROS in the present context is singlet oxygen ( 1 Examples of RNS include NO and NO. According to the present invention, ROS as potential components of wound rinse solutions can also be complexed in other compounds; for example, singlet oxygen in the form of sodium hypochlorite (NaOCl). In the case of complexed singlet oxygen such as NaOCl, the singlet oxygen is then generally released on contact with the wound, as known to those skilled in the art. In one embodiment of the present invention, the wound rinse solution contains approximately 0.01-0.1% by weight NaOCl, preferably approximately 0.01-0.08, approximately 0.02-0.08, approximately 0.02-0.07, approximately 0.02-0.06 or approximately 0.02-0.05 or 0.03-0.05% by weight NaOCl.

[0030] In one embodiment of the present invention, the wound rinse solution contains singlet oxygen ( 1 O2), which, as already mentioned, is complexed with singlet oxygen ( 1 O2), such as sodium hypochlorite (NaOCl). With complexed singlet oxygen such as NaOCl, singlet oxygen is usually released on contact with the wound. In one particular embodiment, the wound rinse solution also contains salt, such as NaCl, and / or sea salt. In one particular embodiment, the salt content (e.g. NaCl content) is less than 5, preferably less than 4 or 3% by weight of the wound rinse solution. In a further embodiment of the invention, the wound rinse solution contains polyhexanide and / or octenidine, preferably polyhexanide. Suitable wound rinse solutions are known to those skilled in the art and can be adjusted to the wound to be treated. In the context of the present invention, the wound rinse solution may be, for example, ActiMaris®, Lavanox®, Kerrasol®, BIOsept® Wound Rinse Solution or Microdacyn60® Wound Care, preferably ActiMaris®, Lavanox® or Kerrasol®, particularly preferably Lavanox® or Kerrasol®.

[0031] The wound to be treated according to the present invention can be in principle any type of wound that is accessible to treatment with wound rinse solution and cold plasma.They are preferably wounds on the skin or mucous membrane, and they are preferably accessible without surgery (superficial wounds).In one embodiment of the present invention, the wound to be treated is infected or inflamed by one or more bacteria and / or viruses, preferably bacteria. Exemplary bacterial infections and inflammations may be caused, for example, by Enterobacter sp. (e.g., E. cloacae), Pseudomonas sp. (e.g., P. aeroginosa), Staphylococcus sp. (e.g., S. aureus), Klebsiella sp. (e.g., K. pneumonia), E. coli, Streptococcus sp., and / or Proteus sp. In one embodiment, the wounds treated according to the invention are acutely or chronically, preferably chronically (chronic wounds), infected or inflamed. "Chronic" in this context may mean that the wound has not healed within at least 4, 6 or 8 weeks after the wound was caused, preferably after at least 4 weeks.

[0032] In the context of the present invention, the wound to be treated is treated using a combination of a wound rinse solution as set forth herein and cold (also referred to as "non-thermal") atmospheric plasma (herein referred to as "cold plasma"). Cold atmospheric plasma (cold plasma) comprises a partially ionized gas (e.g., ambient air, argon, helium mixture (preferably with a small amount of oxygen mixed in), or nitrogen; preferably argon) generated under atmospheric conditions (ambient pressure). The plasma temperature preferably does not exceed 50°C, preferably does not exceed 40°C. In one embodiment, only a maximum of 0.1-10 ppb (parts per billion), for example 0.5-5 ppb or approximately 1 ppb, of ionized particles are present in the cold plasma. In the context of the present invention, the cold plasma can generate electrons, ions, radicals, ROS, RNS and / or UV radiation. The generation and use of cold plasma is known to those skilled in the art, for example as provided by terraplasma medial GmbH (Germany; http: / / terraplasma-medical.com / ). Typical gases for plasma generation according to the invention may include, inter alia, air, argon, helium mixtures (preferably with a small amount of oxygen mixed in), and / or nitrogen, preferably argon. Apparatus according to the invention for generating and using cold plasma and for use in medical treatment are known to those skilled in the art and include, for example, PlasmaDerm® (Cinogy), kINPen® (INP Greifswald), Plasma One (plasma Medical Systems GmbH) and SteriPlas® (Adtec Healthcare). Cold plasma can in principle be used in any suitable manner as known to those skilled in the art and as described, for example, in Eswaramoorthy et al., Biophys (2017), 9: 895-917.

[0033] As already described, the wound is first rinsed with a suitable wound rinse solution in the context of the present invention. The exposure time may vary depending on the wound, typically being approximately 5-10 minutes, preferably approximately 7-8 minutes. Depending on the accessibility of the wound, the wound rinse solution can be applied directly or with the aid of, for example, a soaked compress. Similarly, within the scope of the present invention, infected areas in the vicinity of the wound that are not themselves part of the wound, but which may promote repeated infection of the wound (e.g. cables, tubes, implants or other devices) can be treated with the wound rinse solution. The wound rinse solution can then be removed as far as possible using suitable means (e.g. a compress). In one embodiment of the present invention, the wound rinse solution is not completely dried, so that residual moisture is retained. In a subsequent step of cold plasma treatment, it is also possible according to the present invention to treat the remaining wound rinse solution with cold plasma in addition to the wound or areas in the vicinity of the wound. Thereafter, according to the invention, the wound and, optionally, where appropriate, the infected area in the vicinity of said wound, are treated with cold air plasma. The treatment is carried out depending on the wound, as will be readily apparent to the skilled person. Relevant parameters include the size and depth of the wound and, where appropriate, the degree of infection. A typical treatment time with cold plasma may also be approximately 5-10 minutes, preferably approximately 3-5 minutes; in the case of larger wounds, such as sternum wounds, it may generally be 5-10 minutes. After the plasma treatment, a further step of wound rinsing may then be carried out similarly to the first wound rinsing, where preferably the same wound rinsing solution is used in both cases. In one embodiment of the invention, after the plasma treatment, there is a further step of rinsing with a wound rinsing solution, preferably the same wound rinsing solution as in the previous rinsing. The wound rinsing solution may then be removed again as far as possible by suitable means (e.g. compresses).

[0034] In one embodiment of the invention, the wound rinse solution itself may also be treated with cold plasma, for example for approximately 5-10 minutes, or for approximately 3-5 minutes, as already described above, particularly if the wound rinse solution has not been allowed to dry completely after rinsing the wound.

[0035] As indicated in the context of the present invention, after treatment of the wound with cold plasma or after subsequent rinsing with a wound rinse solution, the wound may be further treated with an activated charcoal dressing, preferably a vacuum activated charcoal dressing, for the treatment of the wound (advanced negative pressure wound therapy (aNPWT)). Examples of suitable activated charcoal dressings are known to those skilled in the art and include Actisorb®, Askina® Carbosorb, CarboFlex®, Vliwaktiv® AG absorbent compress, among others. Dressings composed of activated charcoal and vacuum sponges may be used as vacuum activated charcoal dressings, e.g., as "advanced negative pressure wound therapy" (aNPWT), as known to those skilled in the art. The activated charcoal may fix residual microorganisms under the vacuum sponge, thus reducing the repeated progression of the infection. According to the present invention, the progress of the treatment may thus be further supported by the combination of a wound rinse solution and cold air plasma. In applications according to the invention, activated charcoal dressings are particularly preferred, where the charcoal-containing portion is applied (i.e. placed) directly onto the wound. This allows bacteria to be bound without a barrier. A preferred activated charcoal dressing, which allows for direct application of the charcoal-containing portion of the dressing, is Zorflex® Activated Charcoal (Chemviron, UK).

[0036] In the context of the present invention, unless expressly indicated otherwise, the singular forms always include the corresponding plural forms.

[0037] Furthermore, the expression "and / or" includes both the respective terms "and" and "or" as well as any and all possible combinations of the respective elements connected by "and / or".

[0038] The term "approximately" preferably means within 20%, 10%, 5% or 2% of the corresponding value or range. Furthermore, the exact value or range following the term "approximately" is expressly included.

[0039] The term "comprising" as used herein refers to the inclusion of each feature, term, or value, but not the exclusion of features, terms, or values ​​that are not listed. The aspect of the term "comprising" can also refer to the exclusive term "consisting of," unless expressly indicated otherwise.

[0040] It is to be understood that the invention is not limited to the particular methodology, protocols, materials, reagents, and substances, etc. described herein, as such may vary. The terms used herein are merely used to describe certain embodiments and are not intended to limit the scope of the invention, which is defined solely by the claims.

[0041] All publications and patents cited herein, whether supra or infra, including all patents, patent applications, scientific publications, manufacturer information, instructions, etc., are incorporated herein by reference in their entirety. Nothing herein should be construed as a concession that the invention is not authorized to anticipate such disclosures based on prior invention. To the extent that the referenced material contradicts or is incompatible with this description, the description itself supersedes this material.

[0042] The following examples serve only to illustrate the invention and in no way limit its scope, the object of which is defined by the claims. EXAMPLES

[0043] Example 1 Common treatment regimens Surgical treatment of the wound may be necessary before starting therapy. Open the wound area as completely as possible. Perform general surgical debridement. Remove non-viable tissue and bone parts as necessary. This helps to initially reduce the microbial load and prepare the wound bed. After adequate hemostasis is achieved, the first dressing (activated charcoal NPWT) can be applied.

[0044] The combined therapy according to the present invention is usually performed in the outpatient department. As a result of this less painful procedure, analgesics or even anesthesia standby can generally be omitted. Dressing changes are performed under aseptic conditions (sterile gloves, work surface, face mask). For this reason, optimally two personnel are required to perform this therapy quickly and completely.

[0045] Example 2 Wound rinsing and cold plasma treatment Wound rinsing for releasing singlet oxygen in wounds After removal of the surgical dressing (photographic recording, swabbing), the wound area is rinsed with a wound rinse solution containing activated oxygen (e.g. ActiMaris, Kerrasol, Lavanox). If external access to the body interior is present, e.g. drivelines, the section to be treated is wrapped with an appropriately soaked compress. The exposure time averages 5-8 minutes. Excess liquid is then removed with a dry compress, so that a wet film of the rinse solution remains in the wound bed.

[0046] Cold plasma treatment The wound area to be treated is treated with cold plasma (e.g. SteriPlas from Adtec). Argon plasma is generated from argon gas in an electric field, which then forms reactive oxygen species (ROS) from atmospheric oxygen. Together with a low proportion of UV light, these form active ingredients to combat pathogens and stimulate the body's own cells to better fight infections. In addition to the direct plasma effect (high penetration depth due to the atomic structure), the residue of the rinsing solution extends the so-called plasma action time. The cold plasma exposure time is approximately 5 minutes per treatment area section (i.e., for example, 8-10 minutes with an open sternum).

[0047] Example 3 Wound rinsing with activated oxygen, cold plasma treatment, and wound sealing with activated charcoal NPWT Repeated wound rinsing with release of singlet oxygen Immediately after the cold plasma treatment, the wound bed is treated as thoroughly as possible with rinsing solution (and, if necessary, a wet compress for external access (e.g., driveline)). This is done on the one hand to take advantage of the available treatment time, but also to protect the wound bed from contamination until the occlusive dressing is applied. The exposure time, approximately another 5 minutes, is used to prepare the activated charcoal NPWT dressing in the last treatment step. Just before inserting the activated charcoal film, the liquid is removed with a dry compress.

[0048] Application of Activated Charcoal NPWT Dressing (aNPWT) The NPWT sponge is cut on a sterile pad. The activated charcoal film is placed in the wound bed. It should be noted here that the film, if possible, occludes the entire wound bed (one or two layers) in order to make the best surface contact with the wound tissue. The carbon film should protrude from the wound by 1-2 cm to cover the surrounding skin area (protection of the wound edges to prevent pathogen transfer). The customized NPWT sponge is then inserted and pasted with an occlusive film (Figure 2). In case of deep sternal infections, a double layer application of film and sponge is also possible: first, a layer of activated charcoal to protect the heart, then the intersternal sponge, then activated charcoal for the presternal soft tissues, and finally the surface sponge.

[0049] Replacement interval The aim of aggressive wound treatment is to shorten the treatment time, which should ultimately reduce the risk to the patient (wound complications) and help to reduce costs over the long term. For these reasons, the change interval should be shortened (Figure 3). Whereas a time interval of 4-5 days was common for regular treatment with standard NPWT, dressing changes with cold plasma application should be performed every 2-3 days under this treatment regimen. The shortened change interval prevents re-emergence of pathogens during the NPWT period, which makes it significantly more difficult, especially since fresh active substances (especially singlet oxygen) are applied with each treatment. The activated charcoal film in the sealed wound prevents the transfer of pathogens and thus helps to isolate possible residual sources of infection more quickly.

[0050] Completion of the procedure After the wound bed has solidified (swab analysis results, inflammation values ​​(e.g., CRP course), gross appearance, granulation), the wound is closed. Treatment with rinsing solution and cold plasma can be repeated at any time, including during surgery.

[0051] Example 4 The patient received an artificial heart (LVAD) in 2013. Since autumn 2015, the patient was initially on outpatient treatment for a driveline infection. The first documented driveline treatment with ActiMaris® was performed. A few months later, inpatient admission was requested for surgical correction of the infection. The findings were so striking that the odor of the Pseudomonas infection could be detected before the patient walked through the door. The extent of the infection is shown in Figures 1A and 1B. Surgical correction was performed immediately. After the bleeding tendency had subsided, the patient was treated with the combined method according to the invention. The infection parameters normalized (CRP<0.5) within only 3 weeks (see Figure 1C) and, according to the patient's own request, the patient was discharged, albeit with a wound, to outpatient treatment. It should be noted that treatment with ActiMaris® alone had failed for more than 6 months, resulting in a significant progression of the infection with an increase in infection parameters. After 3 weeks of combined therapy, improvement of the findings shown above could be achieved, accompanied by normalization of infection values.

Claims

1. 1. A wound rinse solution for treating a wound for use in combination with a cold air plasma and vacuum activated charcoal dressing, comprising: The solution comprises: (a) rinsing the wound with a wound rinse solution, followed by: (b) treating the wound rinse solution remaining on the wound with cold air plasma; and thereafter (c) applying the evacuated activated charcoal dressing to the wound.

23. A wound rinse solution for use by the steps comprising:

2. 10. The wound rinse solution of claim 1, wherein the activated charcoal-containing portion of the activated charcoal dressing is applied directly to the wound.

3. The steps of: (d) repeatedly rinsing the wound with a wound rinse solution.

3. The wound rinse solution of claim 1 or 2, further comprising:

4. 4. The wound rinse solution of claim 1, wherein the wound rinse solution contains active oxygen.

5. 5. The wound rinse solution of claim 1, wherein the wound rinse solution contains singlet oxygen.

6. 6. The wound rinse solution of any one of claims 1 to 5, wherein ambient air or argon is used for plasma generation.

7. 7. The wound rinse solution of any one of claims 1 to 6, wherein the salt content of the wound rinse solution is less than 4% by weight.

8. 13. A system for treating a wound comprising the wound rinse solution of claim 1, cold air plasma, and a vacuum activated charcoal dressing.

9. 10. The system of claim 8, wherein the activated carbon dressing comprises an activated carbon-containing portion configured to be applied directly to a wound.

10. 10. The system of claim 8 or 9, wherein the wound rinse solution contains active oxygen.

11. The system of any one of claims 8 to 10, wherein the wound rinse solution contains singlet oxygen.

12. 12. The system of any one of claims 8 to 11, wherein ambient air or argon is used to generate the cold air plasma.

13. 13. The system of any one of claims 8 to 12, wherein the wound rinse solution has a salt content of less than 4% by weight.

14. The system of any one of claims 8 to 13, wherein the system comprises a cold air plasma generator for generating cold air plasma.

Images